Literature DB >> 22876047

Opioid/naloxone prolonged release combinations for opioid induced constipation.

Shailendra Kapoor.   

Abstract

I read with great interest the recent article by Chen et al in a recent issue of your esteemed journal. The article is highly thought provoking. One emerging therapeutic alternative for opioid induced constipation is the emergence of opioid/naloxone prolonged release combinations. For instance, naloxone when administered in a 1:2 ratio with oxycodone reverses the inhibitory effect of oxycodone on the gastrointestinal tract. The advantage of oxycodone/naloxone prolonged release (OXN) is that while its anti-nociceptive efficacy is equivalent to that of oxycodone prolonged release (OXC), it significantly decreases the "Bowel Function Index" thereby ameliorating symptoms of opioid induced constipation to a large extent. Schutter et al in a recent study have reported a decrease in the bowel function index from 38.2 to 15.1. Similarly, Löwenstein et al in another recent study have reported that following a month of therapy, complete spontaneous bowel movements per week is increased from one in OXC therapy to three in OXN therapy.

Entities:  

Keywords:  Cancer; Carcinogenesis; Morphine; Opiod naloxone

Mesh:

Substances:

Year:  2012        PMID: 22876047      PMCID: PMC3413067          DOI: 10.3748/wjg.v18.i29.3921

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  9 in total

1.  Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.

Authors:  O Löwenstein; P Leyendecker; M Hopp; U Schutter; P D Rogers; R Uhl; S Bond; W Kremers; T Nichols; B Krain; K Reimer
Journal:  Expert Opin Pharmacother       Date:  2009-03       Impact factor: 3.889

2.  Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice.

Authors:  U Schutter; S Grunert; C Meyer; T Schmidt; T Nolte
Journal:  Curr Med Res Opin       Date:  2010-06       Impact factor: 2.580

3.  Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer.

Authors:  K E Clemens; I Quednau; E Klaschik
Journal:  Int J Clin Pract       Date:  2011-04       Impact factor: 2.503

4.  Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.

Authors:  Kai Hermanns; Uwe Junker; Thomas Nolte
Journal:  Expert Opin Pharmacother       Date:  2012-01-06       Impact factor: 3.889

5.  Opiate-induced constipation related to activation of small intestine opioid μ2-receptors.

Authors:  Wency Chen; Hsien-Hui Chung; Juei-Tang Cheng
Journal:  World J Gastroenterol       Date:  2012-03-28       Impact factor: 5.742

6.  Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteers.

Authors:  Kevin Smith; Michael Hopp; Gill Mundin; Simon Bond; Paul Bailey; Jo Woodward; Karuppan Palaniappan; Ann Church; Marie Limb; Alyson Connor
Journal:  Expert Opin Investig Drugs       Date:  2011-04       Impact factor: 6.206

7.  Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.

Authors:  A Sandner-Kiesling; P Leyendecker; M Hopp; L Tarau; J Lejcko; W Meissner; P Sevcik; M Hakl; R Hrib; R Uhl; H Dürr; K Reimer
Journal:  Int J Clin Pract       Date:  2010-03-29       Impact factor: 2.503

8.  Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.

Authors:  Kevin Smith; Michael Hopp; Gill Mundin; Petra Leyendecker; Paul Bailey; Birgit Grothe; Reiner Uhl; Karen Reimer
Journal:  Clin Ther       Date:  2008-11       Impact factor: 3.393

9.  A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.

Authors:  Sam H Ahmedzai; Friedemann Nauck; Gil Bar-Sela; Björn Bosse; Petra Leyendecker; Michael Hopp
Journal:  Palliat Med       Date:  2011-09-21       Impact factor: 4.762

  9 in total
  1 in total

1.  Neurochemical phenotype and function of endomorphin 2-immunopositive neurons in the myenteric plexus of the rat colon.

Authors:  Jun-Ping Li; Xi-Yu Wang; Chang-Jun Gao; Yong-Hui Liao; Juan Qu; Zhong-Yi He; Ting Zhang; Guo-Du Wang; Yun-Qing Li
Journal:  Front Neuroanat       Date:  2014-12-16       Impact factor: 3.856

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.